{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:59:36Z","timestamp":1771275576923,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,15]]},"DOI":"10.7759\/cureus.31547","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T21:23:41Z","timestamp":1668547421000},"source":"Crossref","is-referenced-by-count":1,"title":["Prolactinomas in Moroccan Population: Clinical, Paraclinical, Therapeutic, and Evolutionary Aspects"],"prefix":"10.7759","author":[{"given":"Zineb","family":"Elazime","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Amine","family":"Essafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nourelhouda","family":"Remok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayat","family":"Aynaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houda","family":"Salhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan","family":"El Ouahabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson P","year":"2019","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019, 33:101290. 10.1016\/j.beem.2019.101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2008.10.009","article-title":"Prolactinomas: diagnosis and treatment","volume":"38","author":"Delemer B","year":"2008","unstructured":"Delemer B. Prolactinomas: diagnosis and treatment. Presse Medicale (Paris, France: 1983). 2008, 38:117-24. 10.1016\/j.lpm.2008.10.009","journal-title":"Presse Medicale (Paris, France: 1983)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2008.10.009.","article-title":"The epidemiology and genetics of pituitary adenomas","volume":"23","author":"Daly AF","year":"2009","unstructured":"Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas\r\n. Clin Endocrinol Metab. 2009, 23:543-54. 10.1016\/j.lpm.2008.10.009.","journal-title":"Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.05.001","article-title":"Pituitary tumours: pituitary incidentalomas","volume":"23","author":"Molitch ME","year":"2009","unstructured":"Molitch ME. Pituitary tumours: pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab. 2009, 23:667-75. 10.1016\/j.beem.2009.05.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinaemia","volume":"8","author":"Samperi I","year":"2019","unstructured":"Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med. 2019, 8:2203. 10.3390\/jcm8122203","journal-title":"J Clin Med"},{"key":"ref6","article-title":"Ad\u00e9nomes hypophysaires","volume":"19","author":"Jouanneau E","year":"2015","unstructured":"Jouanneau E, Raverot G, Vasiljevic A, et al.. Ad\u00e9nomes hypophysaires . L'encyclop\u00e9die neurochirurgicale. 2015, 19:1-32.","journal-title":"L'encyclop\u00e9die neurochirurgicale"},{"key":"ref7","unstructured":"Hyperprolactin\u00e9mie et troubles de la reproduction. (2015). Accessed. September 10, 2021: https:\/\/core.ac.uk\/download\/pdf\/84058604.pdf."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1023\/b:neon.0000041887.51906.b7","article-title":"Stereotactic radiosurgery for pituitary adenomas: a review of the literature","volume":"69","author":"Laws ER","year":"2004","unstructured":"Laws ER, Sheehan JP, Sheehan JM, Jagnathan J, Jane JA Jr, Oskouian R. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol. 2004, 69:257-72. 10.1023\/b:neon.0000041887.51906.b7","journal-title":"J Neurooncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao A","year":"2003","unstructured":"Colao A, Sarno AD, Cappabianca P, et al.. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003, 148:325-31. 10.1530\/eje.0.1480325","journal-title":"Eur J Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst J","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, et al.. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999, 84:2518-22. 10.1210\/jcem.84.7.5810","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/BF03343573","article-title":"Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma","volume":"22","author":"Cannav\u00f2 S","year":"1999","unstructured":"Cannav\u00f2 S, Curt\u00f2 L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest. 1999, 22:354-9. 10.1007\/BF03343573","journal-title":"J Endocrinol Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.05.003","article-title":"Pituitary tumours: the prolactinoma","volume":"23","author":"Colao A","year":"2009","unstructured":"Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009, 23:575-96. 10.1016\/j.beem.2009.05.003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars M","year":"2008","unstructured":"Kars M, Delgado V, Holman ER, et al.. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008, 93:3348-56. 10.1210\/jc.2007-2658","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21639","article-title":"Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists","volume":"22","author":"Simonis G","year":"2007","unstructured":"Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord. 2007, 22:1936-42. 10.1002\/mds.21639","journal-title":"Mov Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao A","year":"2003","unstructured":"Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003, 349:2023-33. 10.1056\/NEJMoa022657","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13940","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology","volume":"90","author":"Steeds R","year":"2019","unstructured":"Steeds R, Stiles C, Sharma V, Chambers J, Lloyd G, Drake W. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf). 2019, 90:662-9. 10.1111\/cen.13940","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-9589(02)00335-1","article-title":"The role of surgery in the treatment of prolactinomas","volume":"30","author":"Roux FX","year":"2002","unstructured":"Roux FX, Nataf F, Page P, Devaux B , Brami F. The role of surgery in the treatment of prolactinomas. Gynecol Obstet Fertilite. 2002, 30:367-73. 10.1016\/S1297-9589(02)00335-1","journal-title":"Gynecol Obstet Fertilite"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22860","article-title":"The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution","volume":"110","author":"Kong DS","year":"2007","unstructured":"Kong DS, Lee JI, Lim DH, et al.. The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer. 2007, 110:854-60. 10.1002\/cncr.22860","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2000.93.supplement_3.0014","article-title":"Gamma knife radiosurgery for prolactinomas","volume":"93","author":"Landolt AM","year":"2000","unstructured":"Landolt AM, Lomax N. Gamma knife radiosurgery for prolactinomas. J Neurosurg. 2000, 93:14-8. 10.3171\/jns.2000.93.supplement_3.0014","journal-title":"J Neurosurg"},{"key":"ref20","unstructured":"Les ad\u00e9nomes hypophysaires.place de l\u2019irradiation intracr\u00e2nienne en conditions st\u00e9r\u00e9otaxiques (radiochirurgie et radioth\u00e9rapie st\u00e9r\u00e9otaxique) dans le traitement de pathologies non canc\u00e9reuses. (2011). Accessed. November 26, 2021: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2011-12\/rapport_tome_ii__radiotherapie_adenomes_hypophysaires_20...."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen L","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P, et al.. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012, 167:651-62. 10.1530\/EJE-12-0236","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/115719-prolactinomas-in-moroccan-population-clinical-paraclinical-therapeutic-and-evolutionary-aspects","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:52Z","timestamp":1707508192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/115719-prolactinomas-in-moroccan-population-clinical-paraclinical-therapeutic-and-evolutionary-aspects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.31547","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,15]]}}}